Polymersomes for Therapeutic Protein and Peptide Delivery: Towards Better Loading Properties
Chengxu Hua,Liyan Qiu
DOI: https://doi.org/10.2147/ijn.s444910
IF: 7.033
2024-03-08
International Journal of Nanomedicine
Abstract:Chengxu Hua, Liyan Qiu Ministry of Educational (MOE) Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, People's Republic of China Correspondence: Liyan Qiu, Tel/Fax +86 571 87952306, Email Therapeutics based on proteins and peptides have profoundly transformed the landscape of treatment for diseases, from diabetes mellitus to cancers, yet the short half-life and low bioavailability of therapeutic proteins and peptides hinder their wide applications. To break through this bottleneck, biomolecules-loaded polymersomes with strong adjustability and versatility have attracted more and more attentions recently. Loading proteins or peptides into polymersomes is the first but extremely important step towards developing high-quality formulation products. However, increasing protein and peptide loading content is quite challenging due to the inherent nature of self-assembled vesicle formation mechanism and physiochemical characteristics of biomacromolecules. This review highlights the potential of polymersomes as the next-generation therapeutic proteins and peptides carrier and emphatically introduces novel approaches and recent progress to achieve satisfactory encapsulation capability of polymersomes for proteins and peptides. On the one hand, with the help of intermolecular interactions, such as electrostatic, lipid–protein, and hydrophobic interactions, the drug loading could be significantly improved. On the other hand, loading improvement could be attained through innovation of preparation methods, ranging from modified traditional film hydration techniques to the novel phase-guided assembly method. Keywords: protein, peptide, polymersomes, vesicles, drug loading Graphical Therapeutic proteins and peptides are playing an increasingly important role in treating cancers, diabetes, cardiovascular diseases, and other disorders. 1 Both protein and peptide are composed of amino acids, but they are artificially differentiated based on their amino acid units, molecular weights, and spatial conformations. 2 Generally, those with molecular weights greater than 5000 Da are defined as proteins, while those between 500 and 5000 Da are assigned to peptides. 3 Compared to small-molecule drugs, therapeutic proteins provide a larger contact surface area. This greater surface area improves binding specificity and lowers the risk of off-target effects. 4 Furthermore, owing to the presence of abundant reactive amino acid residues, therapeutic proteins and peptides are highly amenable to modifications such as fusion, glycosylation, lipidation, and phosphorylation. 1 Currently, more than 130 therapeutic proteins 1 and around 80 peptides 5 have been used clinically. Statistically, 55% of the marketed therapeutic proteins are indicated for hematology (29%) and oncology (26%), 6 while therapeutic peptides cover the applications in oncology, urology, pain, cardiovascular, respiratory, metabolic, and antimicrobial treatment. 3 According to a biobusiness brief published by Nature Reviews, 5 of the top 10 drugs by worldwide sales in 2022 were protein and peptide drugs. 7 However, it remains quite challenging to promote clinical translation of proteins and peptides. Table 1 summarizes representative examples of innovative dose forms for therapeutic proteins and peptides. Oral administration is always the optimal route for patient compliance. However, only a few oral preparations such as capsules 8 and tablets 9 are clinically available due to poor absorption and easy degradation of peptides and proteins in the gastrointestinal tract. Recently, extended-release capsules (Mycapssa ® ) were developed with transient permeability enhancer (TPE ® ) technology by Chiasma in the USA and was approved by the FDA. Mycapssa ® is applied for long-term maintenance treatment for patients with acromegaly who have tolerated lanreotide or octreotide initial treatment. 10 Another limitation of proteins and peptides is their short half-life. About 569 proteases are equipped in the body to degrade proteins and peptides, resulting in their fast elimination. 11 For example, the half-life of glucagon-like peptide-1 (GLP-1) is merely 1–2 min due to the degradation effect of dipeptidyl peptidase-4. 12 Microspheres present a successful solution to this issue. They enable controlled drug release by encapsulating drugs within polymers. As polymers degrade over time, the drug is released in a slow and continuous manner. This approach enhances drug stability, extends the drug's in vivo half-life, as well as reduces peak-valley fluctuations in plasma drug concentrations. -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology